Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply

Lancet. 2024 Aug 3;404(10451):434. doi: 10.1016/S0140-6736(24)01263-7.

Authors

Hanny Al-Samkari¹, James B Bussel², Yoshi Miyakawa³, Catherine M Broome⁴

Affiliations

¹ Hematology Division, Massachusetts General Hospital, Boston, MA 02139, USA. Electronic address: [email protected].
² Division of Hematology and Medical Oncology and Division of Pediatric Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA.
³ Department of Hematology, Saitama Medical University Hospital, Saitama, Japan.
⁴ Lombardi Cancer Center, Division of Hematology, Georgetown University, Washington, DC, USA.

PMID: 39097394
DOI: 10.1016/S0140-6736(24)01263-7

No abstract available

Publication types

Letter

MeSH terms

Humans
Purpura, Thrombocytopenic, Idiopathic* / drug therapy
Randomized Controlled Trials as Topic